Last edition
News about "AstraZeneca"
AstraZeneca To Invest CAD 820 Mn in Canada to Boost Clinical Delivery Sector
New investment in Canada will contribute to AstraZeneca’s global ambition to achieve USD80 billion in Total Revenue and to bring 20 new medicines to patients around the world by 2030 of which eight new medicines have been delivered to date.
AstraZeneca | 27/01/2025 | By Aishwarya
AstraZeneca Gains CDSCO Nod for Import of Eculizumab in India
Eculizumab is a monoclonal antibody used to treat Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting complement-mediated thrombotic microangiopathy.
AstraZeneca | 18/01/2025 | By Aishwarya
Lunit, AstraZeneca to Develop AI-Powered Digital Pathology Tools for NSCLC
Lunit’s collaboration with AstraZeneca aims to transform the speed and accuracy of detecting actionable mutations in NSCLC.
AstraZeneca | 19/11/2024 | By Aishwarya
AstraZeneca Announces Investment of USD 3.5 Billion in R&D in US
AstraZeneca’s expanding footprint in the US includes, a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts, a next generation manufacturing facility for biologics in Maryland, cell therapy manufacturing capacity on the West and East Coasts and a specialty manufacturing in Texas.
AstraZeneca | 14/11/2024 | By Aishwarya
EMA Accepts Approval for AstraZeneca MAA for Sipavibart
AstraZeneca has announced that its Marketing Authorisation Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients.
AstraZeneca | 02/07/2024 | By Aishwarya | 131
AstraZeneca Completes Acquisition of Fusion
AstraZeneca has completed the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
AstraZeneca | 06/06/2024 | By Aishwarya | 100
Nona Biosciences Signs License Deal with AstraZeneca for Monoclonal Antibody Development
Nona Biosciences has signed a license deal with AstraZeneca for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.
AstraZeneca | 27/05/2024 | By Aishwarya | 144
AstraZeneca to Establish USD 1.5 Billion Manufacturing Facility for ADCs in Singapore
AstraZeneca has decided to build a USD 1.5 billion manufacturing facility in Singapore for antibody-drug conjugates (ADCs), enhancing the global supply of its ADC portfolio.
AstraZeneca | 20/05/2024 | By Aishwarya | 108
AstraZeneca Acquires Fusion Pharmaceuticals to Transform Cancer Treatment
Fusion Pharmaceuticals Inc. has signed a definitive agreement to be acquired by AstraZeneca.
AstraZeneca | 20/03/2024 | By Manvi | 252
AstraZeneca to build production facility in China for COPD inhaler Breztri
AstraZeneca to build production facility in China for COPD inhaler Breztri
AstraZeneca | 24/07/2023 | By Sudeep Soparkar | 562
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy